Mechanism of clinically relevant drug-drug interaction between cerivastatin and gemfibrozil

被引：0
|
作者：
Shitara, Y
Hirano, M
Sato, H
Sugiyama, Y
机构：
[1] Showa Univ, Tokyo 1428555, Japan
[2] Univ Tokyo, Tokyo 1130033, Japan
来源：
DRUG METABOLISM REVIEWS | 2004年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
594
引用
收藏
页码：297 / 297
页数：1
相关论文
共 50 条
  • [21] Clinically Relevant Drug-Drug Interactions in Primary Care
    Carpenter, Mary
    Berry, Holly
    Pelletier, Allen L.
    [J]. AMERICAN FAMILY PHYSICIAN, 2019, 99 (09) : 558 - 564
  • [22] Detrimental antidepressant drug-drug interactions: Are they clinically relevant?
    Preskorn, Sheldon
    Werder, Steve
    [J]. NEUROPSYCHOPHARMACOLOGY, 2006, 31 (08) : 1605 - 1612
  • [23] FURTHER EXPLORATION INTO THE DRUG-DRUG INTERACTION BETWEEN GEMFIBROZIL AND REPAGLINIDE IN RATS: UPTAKE TRANSPORT
    Mccoy, Chase I.
    Stanley, Forrest A.
    Kollu, Chandra
    Muranjan, Seema
    Green, Krystal M.
    Barbara, Joanna E.
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S49 - S50
  • [24] The pharmacokinetic profile of olmesartan medoxomil limits the risk of clinically relevant drug-drug interaction
    Kirch, W
    Laeis, P
    Püchler, K
    [J]. JOURNAL OF HYPERTENSION, 2002, 20 : S368 - S368
  • [25] Mechanism of clinically relevant drug-drug interactions detected by a semi-automatic method
    Mora-Atorrasagasti, Oihana
    Lertxundi-Etxebarria, Unax
    Peral-Aguirregoitia, Javier
    Gabilondo-Zelaia, Itxasne
    Domingo-Echaburu, Saioa
    Jose Martinez-Bengoechea, Maria
    [J]. EJHP PRACTICE, 2008, 14 (05): : 32 - 36
  • [26] Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus
    Leino, Abbie D.
    Emoto, Chie
    Fukuda, Tsuyoshi
    Privitera, Michael
    Vinks, Alexander A.
    Alloway, Rita R.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 (10) : 2944 - 2948
  • [27] ANALYSIS OF DRUG-DRUG INTERACTIONS BETWEEN CERIVASTATIN AND INTERACTING DRUGS, CYCLOSPORINE A AND GEMFIBROZIL, USING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL
    Kim, Soo-Jin
    Yao, Yoshiaki
    Yoshikado, Takashi
    Toshimoto, Kota
    Sugiyama, Yuichi
    [J]. DRUG METABOLISM REVIEWS, 2015, 47 : 115 - 115
  • [28] Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8
    Takagi, Motoi
    Sakamoto, Masaya
    Itoh, Tomoo
    Fujiwara, Ryoichi
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (04) : 288 - 294
  • [29] A reference set of clinically relevant adverse drug-drug interactions
    Kontsioti, Elpida
    Maskell, Simon
    Dutta, Bhaskar
    Pirmohamed, Munir
    [J]. SCIENTIFIC DATA, 2022, 9 (01)
  • [30] A reference set of clinically relevant adverse drug-drug interactions
    Elpida Kontsioti
    Simon Maskell
    Bhaskar Dutta
    Munir Pirmohamed
    [J]. Scientific Data, 9
12345